The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate
the safety and efficacy of three dose levels of AZD1722 in subjects with constipation
predominant IBS (IBS-C) as defined by the ROME III criteria and who have active disease as
determined during a two-week screening period. Subjects who qualify and are randomized into
the study will receive 5, 20, or 50 mg of AZD1722 BID or placebo BID for 12 consecutive
weeks. At the end of this treatment period, subjects will be followed for an additional 4
weeks.